SEC Tracker
Get the app
DYAI · XBRL financial data

Dyadic International financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (DYAI's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers397687*3353861,958817*3949671,165566*1,111961
Cost of goods and services sold106350*144302396353*2986141,024385*792984
Research and development716853*523516460546*495629572458*476333
General and administrative1,2821,652*1,7891,6081,2981,440*1,5961,4371,4811,247*1,7551,690
Operating income (loss)(1,720)(2,169)*(2,126)(2,043)(203)(1,530)*(2,002)(1,729)(1,925)(1,536)*(1,903)(2,054)
Interest income———138127104*88496383*5740
Other income (expense)0(1,018)*——————————
Income tax expense (benefit)——————————00*
Net income (loss)(1,614)(2,072)*(2,010)(2,045)(203)(1,551)*(2,028)(1,794)(1,976)(1,567)*(1,955)(2,124)
Earnings per share, basic USD per share(0.06)(0.07)*(0.07)(0.07)(0.01)—(0.07)(0.06)(0.06)—(0.05)(0.06)
Earnings per share, diluted USD per share———(0.07)(0.01)—(0.07)(0.06)(0.06)(0.04)*(0.05)(0.06)
Weighted average shares, basic thousands of shares28,81128,811*28,828—————————
Weighted average shares, diluted thousands of shares———29,29129,503—29,88730,10234,50835,914*36,39836,439

Balance sheet

CSV

Fiscal quarters (DYAI's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents7,4036,51510,5706,1335,9226,5075,0652,1415,8354,6224,2471,425
Short-term investments—————2,7812,3082,8423,0992,6991,3611,688
Accounts receivable4184662462503532372227159171,0909961,302
Prepaid and other current assets48432824212737430321185340219174419
Total current assets9,0888,06712,54110,50310,6909,8287,8057,40711,5459,8977,7006,407
Right-of-use asset15314113011710592796652392410
Total assets9,2568,21912,68110,63010,8069,9307,8958,13811,6739,9467,8106,537
Accounts payable6006566614335624824487391,2088521,060816
Accrued liabilities6201,0579888718399706919301,3729688911,396
Total current liabilities1,4572,2522,2621,9492,0772,4481,9623,6624,0523,6873,1843,883
Lease liability, non-current1028976634835205————
Total liabilities1,6032,3418,1657,4627,3947,4606,9718,6689,0658,7138,2178,924
Accumulated deficit(78,206)(80,277)(82,287)(84,332)(84,536)(86,086)(88,114)(89,908)(91,884)(93,451)(95,406)(97,530)
Total stockholders' equity7,6535,8794,5163,1683,4122,470924(530)2,6071,232(408)(2,387)
Total liabilities and equity9,2568,21912,68110,63010,8069,9307,8958,13811,6739,9467,8106,537
Common shares outstanding (cover page) thousands of shares28,81128,97429,23729,47829,58930,09130,09136,18836,18836,43936,43936,439

Cash flows

CSV

Fiscal quarters (DYAI's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(1,614)(2,072)*(2,010)(2,045)(203)(1,551)*(2,028)(1,794)(1,976)(1,567)*(1,955)(2,124)
Stock-based compensation281*298*306298247275*225340172192*139144
Net cash from operating activities(1,962)*(923)*(1,113)(1,964)*(201)*(696)*(1,950)(130)*(1,852)*(1,770)*(1,963)(1,818)*
Net cash from investing activities3,527*34*(655)(2,473)*(12)*1,263*482(962)*93*468*1,266(357)*
Net cash from financing activities0*0*5,8240*0*24*240*4,941*(0)*——
Net change in cash1,562*(888)*4,055(4,436)*(212)*585*(1,442)(1,091)*3,181*(1,302)*(698)(2,175)*

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Dyadic International1,425961(1,818)*36.4M1.7 quarters 10-QJun 30, 2026
Aytu Biopharma26,30816,106*4,406*10.9M— 10-KJun 30, 2026
Kala Bio229not reported(1,535)*19.3M4.7 quarters 10-QJun 30, 2026
Lexaria Bioscience3,5000(1,635)*24.8M2.2 quarters 10-QMay 31, 2026
Tenax Therapeutics118,0000*(14,150)*37.4M8.3 quarters 10-QJun 30, 2026
Nanoviricides2,794not reported(2,122)*25.5M1.3 quarters 10-KJun 30, 2026
Curis5,0730(9,646)*2.1M0.5 quarters 10-QJun 30, 2026
Lisata Therapeutics10,4430(2,649)*9.0M3.9 quarters 10-QJun 30, 2026
Pulmatrix2,168not reported(1,106)*3.7M2.0 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.